Blueprint Medicines Corporation released its 2024 Annual Report, detailing global net product revenues for AYVAKIT (avapritinib) of $479 million, representing approximately 135% year-over-year growth. AYVAKIT is now approved and reimbursed for at least one indication in 16 countries, with plans for additional launches in indolent systemic mastocytosis (ISM).
The company provided 2025 product revenue guidance for AYVAKIT of $680 million to $710 million, maintaining its goal of achieving $2 billion in revenue by 2030. Blueprint Medicines also reiterated the estimated $4 billion peak opportunity for its systemic mastocytosis (SM) franchise, supported by growing patient diagnoses and new epidemiology data.
In 2024, Blueprint Medicines initiated the registration-directed Phase 3 HARBOR trial of elenestinib, its next-generation KIT D816V inhibitor. The company also completed a Phase 1 healthy volunteer study of BLU-808, its oral wild-type KIT inhibitor, which demonstrated a well-tolerated profile and rapid, robust, and sustained reductions in serum tryptase. Financially, the company reduced its operating cash burn by over 50% in 2024 and expects further reductions in 2025, ending the year with $863.9 million in cash, supplemented by $78.7 million from an IDRx equity stake sale in Q1 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.